An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

In a recent study published in Neurology - Neuroimmunology Neuroinflammation, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on the progression of clinical disability in ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders through chronic inflammation. However, its role in multiple sclerosis, a ...

In a world built around the ideals of productivity, able-bodiedness, and neurotypicality, individuals suffering from mental and physical disabilities often find themselves pushed to the margins- not ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...

Forbes contributors publish independent expert analyses and insights. Andrew Pulrang writes about disability practices, policy, and culture. Disability activism is empowering. For some disabled people ...